Page 247 - Haematologica May 2020

Cardiac biomarkers in Mayo stage I amyloidosis
Table 1. Baseline patient characteristics (total patients, n=378) including univariate analysis.
Factor assessed for significance
Age (years), >70 years Male sex
Number of organs involved Renal
PNS
ANS
Soft Tissue GI
Spleen
Liver parameters
Albumin (g/L)
Bilirubin (mmol/L)
ALP (U/L
Abnormal ALP (<129U/L)
Liver involvement (ALP 1.5x upper limit) SAP liver involvement
SAP load None/equivocal Small/moderate Large
Cardiac parameters
NT-pro-BNP (ng/L) NT-pro-BNP >152 (ng/L) hsTNT (ng/L)
hsTNT >10 (ng/L) Echocardiogram (mean LVW)
Hematological parameters Presenting κ (mg/L) Presenting λ (mg/L) dFLC (mg/L)
dFLC > 50 mg/L
dFLC >180 mg/L
Treatments
PI based
Alkylator
ASCT
No treatment/ trial treatment* Missing data
Treatment interval 2008-2012 2012-2016 2014-2016 2016-2018
No treatment/ missing data
Median (range), n(%)
69 (35-92), 93 (25) 212 (56.1)
2 (1-7)
277 (73.3)
43 (11.4)
30 (7.9)
44 (11.7)
36 (9.5)
160 (42.3)
76 (27-487) 69 (18- >90) 14 (3.73) 4.28 (0.03- 58.46)
32 (15-50) 5 (1-57) 77 (31-2,113) 47 (22.9) 39 (10.3) 111 (29.4)
122 (32.4) 181 (48.0) 74 (19.6)
161 (8-330) 208 (55) 10 (3-51) 76 (37.1) 10 (6-13)
22.55 (1.5 -935) 26.6( 1.9- 6,180) 1.40 ( 0.1- 6,064) 104 (28.2)
51 (13.5)
248 (67.4) 43 (11.7) 55 (14.9) 24 (6.5) 10 (2.6)
29 (8.4) 88 (25.5) 80 (23.2) 77 (22.3) 33 (9.6)
HR (CI)
1.034(1.010-1.059) 0.850(0.667-1.082)
0.804 (0.486-1.330) 1.612 (0.866-3.000) 2.177 (1.144-4.142) 1.792 (0.982-3.273) 1.428 (0.731-2.789) 1.279 (0.759-2.154)
1.004 (1. 000-1.008) 0.990 (0.972-1.008) 2.11 (0.262-17.047) 0.99 (0.997-1.001)
0.994(0.968-1.020) 1.00(0.998-1.001) 0.923 (0.561-1.519) 0.872(0.352-2.155) 1.518 (0.797-2.891) 0.750 (0.443-1.269)
0.956(0.489-1.869)
1.006 (1.003-1.009) 2.413 (1.448-4.021) 1.032 (1.011-1.054) 1.249(0.554-2.813) 0.998(0.820-1.215)
1.101 (0.847-1.203) 0.991 (0.831-1.181) 0.991 (0.831-1.181) 1.431 (0.859-2.384) 1.590(0.848-2.979)
0.732 (0.417-1.287) 1.560 (0.937-2.599) 1.084 (0.529-2.224) 0.476 (0.143-1.591)
Cox regression P 0.005
0.186
0.396 0.132 0.018 0.057 0.297 0.354
0.036 0.274 0.483 0.198
0.633 0.630 0.753 0.766 0.204 0.284 0.894
<0.001 0.001 0.003 0.592 0.984
0.916 0.917 0.919 0.202 0.143
0.279 0.088 0.825 0.137
Renal parameters
Creatinine (mmol/L) eGFR (mL/min) EGFR < 30 mL/min Proteinuria (g/24h)
*Trial treatment MLN9708. PNS: peripheral nervous system ; ANS: autonomic nervous system ; GI: gastrointestinal; NT-pro BNP: N-terminal pro b-type natriuretic peptide; hsTNT: high-sensitive cardiac troponin T; dFLC: difference between involved and uninvolved serum free light chains; ALP: alkaline phosphatase; SAP: 123I labelled serum amyloid P com- ponent (SAP) scintigraphy; LVW: left ventricle wall; eGFR: estimated glomerular filtration rate; Imid: immunomodulatory therapy: PI: proteasome inhibitor; HR: hazard ratio; CI: confidence interval.
haematologica | 2020; 105(5)
1407